Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy.

ABSTRACT:

Background

Minimal disease quantification may predict event-free survival (EFS) and overall survival (OS).

Methods

We evaluated mRNA expression of five neuroblastoma-associated genes (NB5 assay) in bone marrows (BM) of patients with newly diagnosed high-risk neuroblastoma who received consistent immunotherapy. mRNA expression of CHGA, DCX, DDC, PHOX2B, and TH genes in BM of 479 patients enrolled on the immunotherapy arm of Children's Oncology Group trials ANBL0032 and ANBL0931 was evaluated using real-time polymerase chain reaction (PCR)-based TaqMan low-density array. Results from end-consolidation and end-therapy were analyzed for association with five-year EFS/OS and patient and tumor characteristics. Tests of statistical significance were two-sided.

Results

NB5 as

SUBMITTER: Asgharzadeh S 

PROVIDER: S-EPMC9329214 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature